You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

394 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For relapsed and refractory Mantle Cell Lymphoma, according to clinical criteria
Feb 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Apr 2018
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2017
Regimen
Intent: Palliative
May 2024
Regimen
Intent: Palliative
May 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Feb 2023
Regimen
Cancer Type:
Hematologic, 
Myelodysplastic Syndrome (MDS)
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
Aug 2023

Pages